

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claim 1 (currently amended):** A bioadhesive pharmaceutical formulation comprising an active agent and a mucoadhesive carrier for the active agent, wherein the mucoadhesive carrier comprises a  $\beta$ -limit dextrin which is obtained by hydrolyzing a waxy starch, and said formulation is in the form of a buccal melt product comprising a freeze-dried matrix, wherein the buccal melt product is a wafer.

**Claim 2 (cancelled).**

**Claim 3 (previously presented):** A bioadhesive pharmaceutical formulation as claimed in Claim 1 in which the active agent is a pharmaceutically active agent.

**Claims 4-6 (cancelled).**

**Claim 7 (previously presented):** A bioadhesive pharmaceutical formulation as claimed in Claim 1 which is a thin film.

**Claim 8 (previously presented):** A bioadhesive pharmaceutical formulation as claimed in Claim 1 further including at least one carbohydrate.

**Claim 9 (previously presented):** A bioadhesive pharmaceutical formulation as claimed in Claim 8 in which the at least one carbohydrate is a polysaccharide.

**Claim 10 (currently amended):** A bioadhesive pharmaceutical formulation as claimed in Claim 8 in which the at least one carbohydrate is selected from the group consisting of: alginate; pectin; and derivatives of alginate and pectin.

**Claim 11 (previously presented):** A bioadhesive pharmaceutical formulation as claimed in Claim 10 in which the alginate comprises between 1 and 50% of the formulation (w/w).

Claim 12 (**previously presented**): A bioadhesive pharmaceutical formulation as claimed in Claim 11 in which the alginate comprises between 10 and 30% of the formulation (w/w).

Claims 13-25 (**cancelled**).

Claim 26 (**withdrawn; currently amended**): A method for delivering an active agent to a mucosal membrane of a mammal comprising administering to said mammal a bioadhesive formulation comprising said active agent and a mucoadhesive carrier for the active agent, wherein the mucoadhesive carrier comprises a  $\beta$ -limit dextrin which is obtained by hydrolyzing a waxy starch, and said formulation is ~~in the form of~~ a buccal melt product comprising a freeze-dried matrix, wherein the buccal melt product is a wafer.

Claim 27 (**withdrawn**): A method according to Claim 26, wherein the active agent is a breath freshener.

Claim 28 (**withdrawn**): A method according to Claim 27, wherein the formulation is a thin-film breath freshener.

Claim 29 (**withdrawn**): A method according to Claim 26, wherein the active agent is a pharmaceutically active agent.

Claims 30-37 (**cancelled**).

Claim 38 (**new**): A bioadhesive formulation as claimed in Claim 1 in which the active agent is a breath freshener.